Next Article in Journal / Special Issue
Clinical Development of c-MET Inhibition in Hepatocellular Carcinoma
Previous Article in Journal
The Role of Environmental Factors in the Development of Celiac Disease: What Is New?
Previous Article in Special Issue
Synergistic Anticancer Activities of Natural Substances in Human Hepatocellular Carcinoma
Article Menu

Export Article

Open AccessReview
Diseases 2015, 3(4), 294-305;

Targeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma

Department of Medical Oncology, Guy’s and St. Thomas’ NHS Foundation Trust, SE1 9RT London, UK
Department of Oncology, King’s College Hospital, SE19 1RT London, UK
Author to whom correspondence should be addressed.
Academic Editor: Stephen L. Chan
Received: 20 August 2015 / Revised: 28 September 2015 / Accepted: 20 October 2015 / Published: 28 October 2015
(This article belongs to the Special Issue Targeted Therapy of Hepatocellular Carcinoma: Present and Future)
Full-Text   |   PDF [912 KB, uploaded 28 October 2015]   |  


Hepatocellular carcinoma (HCC) is a lethal cancer with limited systemic therapeutic options. Liver carcinogenesis is a complex procedure and various pathways have been found to be deregulated which are potential targets for novel treatments. Aberrant signalling through FGF19 and its receptor FGFR4 seems to be the oncogenic driver for a subset of HCCs and is associated with poor prognosis. Inhibition of the pathway in preclinical models has shown antitumour activity and has triggered further evaluation of this strategy to in vivo models. This review aims to describe the role of the FGF19/FGFR4 pathway in hepatocellular carcinoma and its role as a potential predictive biomarker for novel targeted agents against FGF19/FGFR4 signalling. View Full-Text
Keywords: hepatocellular carcinoma; FGF19; FGFR4; β-Klotho hepatocellular carcinoma; FGF19; FGFR4; β-Klotho

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Repana, D.; Ross, P. Targeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma. Diseases 2015, 3, 294-305.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Diseases EISSN 2079-9721 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top